Article
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Frontiers in immunology - 1 Jan 2022
Zhang Wengang, Xia Handai, Yang Rui, Zhang Yuqing, Zheng Qi, Shang Xiaoling, Liu Ni, Ma Xinchun, Wei Chenxi, Chen Hang, Mu Xin, Wang Xiuwen, Liu Yanguo
Abstract excerpt
Background: The emergence of immune checkpoint inhibitors (ICIs) has significantly improved the clinical outcomes of patients with metastatic melanoma. However, survival benefits are only observed in a subset of patients. The fibroblast growth factor receptor (FGFR) family genes are frequently mutated in melanoma, yet their impacts on the efficacy of ICIs remain unclear. Our study aimed to explore the association...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.